After a small cancer drug study yielded the unprecedented result of 100 percent of participants entering remission, oncologists — and patients — wonder if the approach from the experimental drug trial can apply to other types of cancer.
BOSTON—Harvard Business School (HBS) has named its 2022-23 Blavatnik Fellows and the program’s ninth cohort. Launched in 2013, the Blavatnik Fellowship in Life Science Entrepreneurship is part of a gift to Harvard University from the Blavatnik Family Foundation. This program supports HBS alumni and Harvard-affiliated postdocs as they build their promising life science ventures by developing their leadership talents and providing mentorship and community during their entrepreneurial journey.
Read More
Read More